PMID- 21174145
OWN - NLM
STAT- MEDLINE
DCOM- 20110803
LR  - 20211020
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 25
IP  - 1
DP  - 2011 Feb
TI  - Achievement of lipid targets with the combination of rosuvastatin and fenofibric 
      Acid in patients with type 2 diabetes mellitus.
PG  - 47-57
LID - 10.1007/s10557-010-6273-5 [doi]
AB  - OBJECTIVE: The objective of this study was to assess the proportion of patients 
      with type 2 diabetes mellitus (T2DM) attaining individual and combined targets of 
      low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol 
      (HDL-C), triglycerides (TG), non-HDL-C, and apolipoprotein B (ApoB) after 
      treatment with rosuvastatin (R) + fenofibric acid (FA) compared with 
      corresponding-dose R monotherapy. METHODS: This post hoc analysis evaluated data 
      from the T2DM subset of patients with mixed dyslipidemia (LDL-C >/=130 mg/dL, HDL-C 
      <40/50 mg/dL in men/women, and TG >/=150 mg/dL) from 2 randomized studies. Patients 
      included in the analysis (N = 456) were treated with R (5, 10, or 20 mg), FA 135 
      mg, or R (5, 10, or 20 mg) + FA 135 mg for 12 weeks. Attainment of LDL-C <100 
      mg/dL, HDL-C >40/50 mg/dL in men/women, TG <150 mg/dL, non-HDL-C <130 mg/dL, ApoB 
      <90 mg/dL, and the combined targets of these parameters was assessed. RESULTS: 
      Treatment with R + FA resulted in a significantly higher proportion of patients 
      achieving optimal levels of HDL-C (46.8% vs. 20.8%, P = 0.009 for R 10 mg + FA), 
      TG (60.0% vs. 34.0%, P = 0.02 for R 10 mg + FA; 54.0% vs. 26.4%, P = 0.005 for R 
      20 mg + FA), non-HDL-C (55.1% vs. 36.4%, P = 0.04 for R 5 mg + FA), ApoB (58.0% 
      vs. 36.4%, P = 0.02 for R 5 mg + FA); and the combined targets of LDL-C, HDL-C, 
      and TG (28.3% vs. 8.3%, P = 0.02 for R 10 mg + FA) and all 5 parameters (26.1% 
      vs. 8.3%, P = 0.03 for R 10 mg + FA) than corresponding-dose R monotherapies. 
      CONCLUSIONS: A significantly greater proportion of T2DM patients achieved 
      individual and combined lipid targets when treated with the combination of R + FA 
      than corresponding-dose R monotherapies.
FAU - Rosenson, Robert S
AU  - Rosenson RS
AD  - Mount Sinai Heart, Mount Sinai School of Medicine, New York, NY 10029-6574, USA. 
      robert.rosenson@mssm.edu
FAU - Carlson, Dawn M
AU  - Carlson DM
FAU - Kelly, Maureen T
AU  - Kelly MT
FAU - Setze, Carolyn M
AU  - Setze CM
FAU - Hirshberg, Boaz
AU  - Hirshberg B
FAU - Stolzenbach, James C
AU  - Stolzenbach JC
FAU - Williams, Laura A
AU  - Williams LA
LA  - eng
SI  - ClinicalTrials.gov/NCT00300482
SI  - ClinicalTrials.gov/NCT00463606
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Apolipoproteins B)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 0 (Triglycerides)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - BGF9MN2HU1 (fenofibric acid)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Anticholesteremic Agents/adverse effects/therapeutic use
MH  - Apolipoproteins B/*blood
MH  - Cholesterol, HDL/*blood
MH  - Cholesterol, LDL/*blood
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Dyslipidemias/blood/drug therapy
MH  - Female
MH  - Fenofibrate/adverse effects/*analogs & derivatives/therapeutic use
MH  - Fluorobenzenes/adverse effects/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pyrimidines/adverse effects/*therapeutic use
MH  - Rosuvastatin Calcium
MH  - Sulfonamides/adverse effects/*therapeutic use
MH  - Triglycerides/*blood
PMC - PMC3070080
EDAT- 2010/12/22 06:00
MHDA- 2011/08/04 06:00
PMCR- 2010/12/21
CRDT- 2010/12/22 06:00
PHST- 2010/12/22 06:00 [entrez]
PHST- 2010/12/22 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
PHST- 2010/12/21 00:00 [pmc-release]
AID - 6273 [pii]
AID - 10.1007/s10557-010-6273-5 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2011 Feb;25(1):47-57. doi: 10.1007/s10557-010-6273-5.